Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 10

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 10
---
 |
| Paul J. Diaz +                     |     | Current President and Chief Executive Officer of Myriad Genetics, Inc. (until April 30, 2025)                                  |     |           2020 |     |             |     |                  |     |                             |

AFC = Audit and Finance Committee

CHCC = Compensation and Human Capital Committee

NGC = Nominating and Governance Committee

RPIC = Research and Product Innovation Committee

* = Chair of the Board

^ = Chair of the Committee

+ = Mr. Diaz announced that he will resign from his positions as President and Chief Executive Officer and Director effective April 30, 2025 .

++ = Mr. Raha, our current Chief Operating Officer, will succeed Mr. Diaz as President and Chief Executive Officer and as a Class II Director effective April 30, 2025, and will stand for election at the Annual Meeting.

#### 2024 Business Performance Highlights
During fiscal year 2024, we continued to make progress on our strategic growth plan. Some of our fiscal year 2024 business highlights include:

Financial Performance

• Revenues : Our revenues increased 11% from fiscal year 2023 to $838 million. Our revenue growth was driven by Pharmacogenomics revenue growth of 23% year-over-year as well as Prenatal and Hereditary Cancer revenue growth year-over-year of 17% and 11%, respectively.

2

• GAAP and Adjusted Operating Income (Loss) : GAAP operating loss was $(123.5) million and adjusted operating income was $21.8 million, a year-over-year increase of $47.3 million compared to fiscal year 2023 adjusted operating loss of $(25.5). (1)

• GAAP and Adjusted EBITDA : GAAP net loss was $(127.3) million while adjusted EBITDA was $40.4 million, an improvement of $51.9 million compared to fiscal year 2023 adjusted EBITDA of $(11.5) million. (1)

• GAAP and Adjusted Earnings (Loss) Per Share: GAAP loss per share was $(1.41) while adjusted earnings per share was $0.14, an improvement of $0.41 over fiscal year 2023 adjusted loss per share of $(0.27). (1)

• GAAP and Adjusted Operating Expenses : GAAP operating expenses were $708.9 million and adjusted operating expenses were $566.9 million. Adjusted